Investigation of the effects of synbiotics (Lactobacillus,Bifidobacterium/oligosaccharide) on chronic inflammation in type 2 diabetes mellitus
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000032057
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Not provided
Exclusion Criteria
1) liver cirrhosis and renal failure (including hemodialysis and serum creatinine 1.5mg/dL and over) 2) type 1 diabetes 3) inflammatory bowel disease 4) past history of digestive surgery 5) milk allergy 6) not suitable for the study (irregular visit)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways do Lactobacillus/Bifidobacterium synbiotics modulate in type 2 diabetes mellitus chronic inflammation?
How effective are synbiotics compared to standard-of-care anti-inflammatory therapies in T2DM patients with metabolic syndrome?
What are the primary clinical endpoints in JPRN-UMIN000032057 regarding synbiotic effects on T2DM inflammation?
Which gut microbiota-derived biomarkers correlate with synbiotic efficacy in reducing C-reactive protein levels in T2DM?
Are there synergistic effects of combining synbiotics with GLP-1 receptor agonists in managing T2DM-related systemic inflammation?